bluuebunny/crossref_metadata_2025_split huggingface dataset:
Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection
Authors: Stalter Randy M , Baeten Jared M , Donnell Deborah , Spinelli Matthew A , Glidden David V , Rodrigues Warren C , Wang Guohong , Vincent Michael , Mugo Nelly , Mujugira Andrew , Marzinke Mark , Hendrix Craig , Gandhi Monica ,   for the Partners PrEP Study Team, Celum Connie , Baeten Jared M , Donnell Deborah , Coombs Robert W , Lingappa Jairam R , McElrath M Juliana , Fife Kenneth H , Were Edwin , Tumwesigye Elioda , Ndase Patrick , Katabira Elly , Katabira Elly , Ronald Allan , Bukusi Elizabeth , Cohen Craig R , Wangisi Jonathan , Campbell James D , Tappero Jordan W , Kiarie James , Farquhar Carey , John-Stewart Grace , Mugo Nelly R , Ngure Kenneth , Campbell James D , Tappero Jordan W , Wangisi Jonathan 
Published: June 2020

Abstract
New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.
Seasonal Influenza Vaccination During Pregnancy and the Risk of Major Congenital Malformations in Live-born Infants: A 2010–2016 Historical Cohort Study
Authors: Peppa Maria , Thomas Sara L , Minassian Caroline , Walker Jemma L , McDonald Helen I , Andrews Nick J , Kempley Stephen T , Mangtani Punam 
Published: June 2020

Abstract

Background
Available evidence indicates that seasonal inactivated influenza vaccination during pregnancy protects both the mother and her newborn and is safe. Nevertheless, ongoing safety assessments are important in sustaining vaccine uptake. Few studies have explored safety in relation to major congenital malformations (MCMs), particularly in the first trimester when most organogenesis occurs.

Methods
Anonymized UK primary care data (the Clinical Practice Research Datalink), including a recently developed Pregnancy Register, were used to identify live-born singletons delivered between 2010 and 2016. Maternal influenza vaccination was determined using primary care records and stratified by trimester. Ascertainment of MCMs from infant primary care records was maximized by linkage to hospitalization data and death certificates. The relationship between vaccination and MCMs recorded in the year after delivery and in early childhood was then assessed using multivariable Cox regression.

Results
A total of 78 150 live-birth pregnancies were identified: 6872 (8.8%) were vaccinated in the first trimester, 11 678 (14.9%) in the second, and 12 931 (16.5%) in the third. Overall, 5707 live births resulted in an infant with an MCM recorded in the year after delivery and the adjusted hazard ratio when comparing first-trimester vaccination to no vaccination was 1.06 (99% CI, .94–1.19; P = .2). Results were similar for second- and third-trimester vaccination and for analyses considering MCMs recorded beyond the first birthday.

Conclusions
In this large, population-based historical cohort study there was no evidence to suggest that seasonal influenza vaccine was associated with MCMs when given in the first trimester or subsequently in pregnancy.
The impact of age on patients undergoing transthoracic esophagectomy for cancer
Authors: Madhavan Anantha , Kamarajah Sivesh K , Navidi Maziar , Wahed S , Immanuel Arul , Hayes Nick , Griffin S Michael , Phillips Alexander W 
Published: June 2020

Summary
To compare long-term and short-term outcomes in patients &lt;70 years old with those ≥ 70 years old, who underwent transthoracic esophagectomy for carcinoma. With an ageing population more patients, with increasing co-morbidities are being diagnosed with potentially curable esophageal cancer. Concerns exist regarding offering older patients esophagectomy, conversely undue prejudice may exists that may prevent surgery being offered. Consecutive patients from a single unit between January 2000 and July 2016 that underwent trans-thoracic esophagectomy with or without neoadjuvant treatment for carcinoma were included. Short-term outcomes including morbidity, mortality, length of stay and long-term survival were compared between those &lt;70 and those ≥ 70. This study identified 992 patients who underwent esophagectomy during the study period, of which 302 (30%) ≥ 70 years old. Greater proportion ≥ 70 years old had SCC (squamous cell carcinoma) (23%) than &lt;70 (18%) (p = 0.07). Patients ≥ 70 years old were noted to have higher ASA Grade 3 (34% vs 25%, p = 0.004) and were less likely to receive neoadjuvant treatment (64% vs 45% p&lt;0.001). Length of stay was longer in ≥ 70 (14 vs 17 days p&lt;0.001), and there were more complications (63% vs 75% p&lt;0.001). In hospital mortality was higher in ≥ 70 (2% vs 5% p = 0.026). Overall survival was 50 months in &lt;70 vs 36 months in ≥ 70 (p = &lt;0.001). In &lt;70s with adenocarcinoma, overall survival was 52 months vs 35 months in the ≥ 70 (p&lt;0.001). No significant difference in survival in patients with SCC, 49 months in &lt;70 vs 54 months in ≥ 70 (p = 0.711). Increased peri-operative morbidity and mortality combined with the reduction in the long term survival in the over 70s cohort should be addressed when counselling patients undergoing curative resection for oesophageal cancer.
P1383Procedural differences during de novo paroxysmal atrial fibrillation ablation with a contact force-sensing ablation catheter between Europe and U.S
Authors: Ramanna H , Lloret J L , Zahwe F , Porterfield C , Trines S , Djajadisastra I , Gibson D , Gururaj A , Alizadeh Dehnavi R , Raine D , James S , Razak E , Oommen S , Tao C , Olson N 
Published: June 2020

Abstract

Background
Although pulmonary vein isolation (PVI) is considered the standard approach of atrial fibrillation ablation worldwide, procedural practice during the ablation varies by geographical region. Using the same magnetic sensor enabled contact force-sensing ablation catheter for the treatment of de novo paroxysmal atrial fibrillation, a comparison of procedural detail between Europe and U.S operators can provide insights into geographic specific clinical practices.

Purpose
To characterize and compare procedural differences during paroxysmal atrial fibrillation ablation performed with a magnetic sensor enabled contact force-sensing catheter across European and U.S. centers.

Methods
Procedural data were prospectively collected in clinical cases performed with a new magnetic sensor enabled, contact force ablation catheter within the first 6 months of use at participating centers in Europe and the U.S. Procedure time, PVI time, PVI confirmation method, fluoroscopy usage and lesion delivery parameters were analyzed based on geographies.

Results
A total of 131 cases across 35 centers in 11 European countries, and 95 cases across 26 U.S. centers were analyzed. Target geometry was created with the ablation catheter in 94 out of 131 (71.8%) European cases, while only 5 out of 95 U.S. cases (5.3%) reported the use of the ablation catheter for model creation. Although a steerable sheath (64.1% and 67.3%) was commonly used with the ablation catheter in both geographies, difference in the utilization of bidirectional contact force catheter (52.7% and 90.5%) and the automated lesion marking module (76.3% and 81.1%) were observed in European and U.S. cases, respectively. The use of adenosine or isoproterenol to confirm PVI was reported in 25% and 64% of the European and U.S. cases. Average waiting periods were 18.2 minutes and 26.5 minutes from reported European and U.S. cases. Total procedural time, mapping time, and fluoroscopy time were similar between European and U.S. cases. (Table). First pass PVI were 66.4% and 72.6% for European and U.S. cases, respectively.

Conclusion
Total procedural time and RF time were similar between European and U.S. cases during de novo paroxysmal atrial fibrillation ablation using the same ablation catheter. Differences in workflow including the use of a mapping catheter for geometry creation and waiting period were observed between the two geographies.
Summary of procedural details De novo PAF N Procedural time(min) Mapping time (min) PVI time (min) Total RF time (min) Fluoro time( min) Europe 131 144.0 ± 56.9 16.6 ± 17.1 69.8 ± 35.0 33.2 ± 15.6 11.6 ± 10.1 U.S. 95 137.6 ± 64.8 18.1 ± 23.5 58.8 ± 31.5 32.3 ± 22.2 12.0 ± 15.8
P936Atrial remodeling in rat hearts after exposure to high-intensity infrasound
Authors: Lousinha A , Pereira G , Borrecho G , Brito J , Oliveira De Carvalho A , Freitas D , Oliveira P , Oliveira M J , Antunes E 
Published: June 2020

Abstract

Background
Noise is an important environmental risk factor. Industrial environments are rich in high-intensity infrasound (hi-IFS), which we have found to induce myocardial and coronary perivascular fibrosis in rats. Recently, a significant association between noise exposure and the incidence of atrial fibrillation (AF) was found in large cohort studies but the pathophysiology is unclear. Atrial fibrosis remains the cornerstone of atrial pathology in AF. Purpose: We hypothesized that rats exposed to hi-IFS develop atrial remodeling involving fibrosis and connexin 43, which we sought to evaluate. Material and Methods: Seventy-two Wistar rats, half exposed to hi-IFS (120dB, &lt;20Hz) during a maximum period of 12 weeks and half age-matched controls, were studied. Atrial fibrosis was analyzed by Chromotrope-aniline blue staining. The immunohistochemical evaluation of Cx43 was performed using the polyclonal antibody connexin-43m diluted 1:1000 at 4ºC overnight. Digitized images were obtained with an optical microscope using 400× magnifications. The measurements were performed using image J software. A two-way ANOVA model was used to compare the groups. Results: The mean values of the ratio "atrial fibrosis / cardiomyocytes" increased to a maximum of 0,1095 ± 0,04 and 0,5408 ± 0,01, and of the ratio "CX43 / cardiomyocytes" decreased to 0,0834 ± 0,03 and 0,0966 ± 0,03, respectively in IFS-exposed rats and controls. IFS-exposed rats exhibited a significantly higher ratio of fibrosis (p &lt; 0,001) and lower ratio of Cx43 (p = 0,009). Conclusion: High-intensity infrasound exposure triggers atrial remodeling in rat hearts. Whether this finding correlates to arrhythmogenic substrate in noise induced-AF is not known and reinforces the need for further experimental studies.
Table 1 Time of exposure (weeks) Group IFS (n = 36) Group CTL (n = 36) P value Ratio of atrial fibrosis / cardiomyocytesMean ± SD 1 0,0896 ± 0,04 0,0460 ± 0,03 0,007 6 0,0936 ± 0,03 0,0491 ± 0,01 0,001 12 0,1095 ± 0,04 0,0541 ± 0,01 0,001 Ratio of atrial CX43 / cardiomyocytesMean ± SD 1 0,1100 ± 0,03 0,1371 ± 0,03 0,047 6 0,0829 ± 0,04 0,1036 ± 0,03 0,170 12 0,0834 ± 0,03 0,0966 ± 0,03 0,259 Mean ± SD of the two measured outcomes in the two groups. IFS – Infrasound; CTL – Control; SD – standard deviation; Cx43 – Connexin 43
Abstract Figure. Atrial fibrosis and Cx43 /cardiomyocytes
P1021Low incidence of atrial tachycardia following ablation of low voltage areas in sinus rhythm for persistent atrial fibrillation
Authors: Lepillier A , Copie X , Escande W , Niro M , Paziaud O , Piot O 
Published: June 2020

Abstract
. Background: Dedicated ablation strategies for persistent atrial fibrillation (AF) have shown a limited success rate with frequent atrial tachycardia (AT) occurrence. Recent studies suggest that atrial arrhythmogenic sites are related to tissular heterogeneities and increased fibrosis can be identified as reduced bipolar voltage areas.
. Purpose: Targeting low voltage areas (LVA) in addition to PVI may represent an efficient strategy for the ablation of persistent AF, and may limit the risk of AT recurrence.
. Methods: We prospectively included consecutive patients with symptomatic persistent AF. The ablation strategy consisted of the following steps: circumferential pulmonary vein isolation (CPVI), Sinus rhythm restoration by electrical cardioversion, voltage map performed in sinus rhythm. Complementary RFA was guided by low voltage areas (0.2-0.4 mV). Success was defined as freedom from AF/ atrial flutter or atrial arrhythmia at 12 months or more.
. Results: 101 patients (mean age: 62.5 +/- 10.4 years, men 73%) were included with persistent AF or long standing AF (7%). Procedure time was: 154 ± 25 min and fluoroscopy time: 184 ± 90 sec. Time of RFA was 44.7 +/- 12 min. Mean LA volume was 182 +/- 38 mL. LVA were found in 50 patients (49.5%). The distribution of these areas was: 30 anterior wall 29.7%), 21 septum (20.7%), 19 roof (18.8%), 5 inferior (4.9%), 11 left appendage (10.8%), 6 posterior (5.9%), 3 mitral isthmus (3%). RF ablation was realized for all LVA and homogenisation was attempt. After a single procedure at a mean FU of 12 months, 72.3% of patients were free of symptomatic AF. 27 patients had recurrence of atrial AF: 7 permanent, 15 persistent and 5 paroxysmal AF. Predictive factors of recurrence of AF were: long standing persistent AF, large left atrial volume (&gt; 205 mL), shorts AF cycle length (&lt; 168 ms) and reduce LEVF (&lt; 45%). Atrial tachycardia occurred in 5 patients (4,9%). Mechanisms of AT were: typical cavo-tricuspid flutter in one patient, peri-mitral flutter in 2 patients, and atrial focal tachycardia (close to pulmonary veins) in 2 patients.
. Conclusion: These results suggest that PVI with complementary RF ablation guided on low voltage areas is an efficient strategy for symptomatic persistent AF, and reduce the recurrence of AT following this ablation strategy.
P563Hemoptysis after cryoablation for atrial fibrillation
Authors: Kumar N , Aksoy I 
Published: June 2020

Abstract

Aim
Cryoballoon is a widely used tool for ablation for atrial fibrillation (AF). There are several complications after cryoablation. This paper assesses the incidence rate and severity of hemoptysis after cryo ablation for AF.

Methods
For current systemic review and meta-analysis, literature has been reviewed from 2008 to 2019 focusing on the incidence of hemoptysis after cryoballoon ablation for atrial fibrillation catheter ablation in PubMed, Cochrane library and EMBASE databases.

Results
This meta-analysis included 3534 patients from 20 studies; of mean age 54.0 ± 10.9 years. All patients had cryoballoon ablation for paroxysmal or persistent AF refractory to treatment and follow up duration for 8.2 ± 5.9 months with mean procedure duration of 153.4± 65.4 minutes. The mean cryoablation duration was 869.4 ± 148 sec with mean temperature of -59.7 ± 5.1 °C and a total of 109 patients (3.08%) had hemoptysis which was mild in the majority of cases (76.1%), mild to moderate in 20.2% and severe in only 3.7%. Hemoptysis onset was at 29.0 ± 56.5 day with median of 7 days, range (2 hours to 210 days). In 11 studies hemoptysis occurred early in 51 patients (95% CI for I2 was 0.0% to 0.0, P =0.95, I2 was 0.0%), but in 9 studies, hemoptysis occurred late in 58 patients (95% CI for I2 was 0.0% to 0.0, P =0.96, I2 was 0.0%).

Conclusion
Mild hemoptysis is experienced by significant number of cryoballoon AF ablation patients and severe type in 3.5 % attributed to significantly lower temperature in inferior pulmonary veins and is more often associated with bigger cryoballoon.
Abstract Figure. Overview of the manuscripts selection
P959Influence of complex reentrant atrial circuits on tachycardia cycle length
Authors: Alonso C , Rodriguez Font E , Guerra Ramos J , Campos Garcia B , Moreno Weidman Z , Mendez Zurita F , Mogro J , Garcia Mancebo S , Espinosa Viamonte H , Gonzalez Matos C , Maldonado Chavez J 
Published: June 2020

Abstract

Funding Acknowledgements
NA

OnBehalf
NA

Background
Ablation of left atrial reentrant tachycardias (ART) is challenging since they usually occur in the setting of complex diseased atrial tissue either in patients with structural heart disease or after ablation of atrial fibrillation. In these cases, scarred tissue or previous ablation lines make the circuits more complex. We have developed a mapping approach in which an activation map that only contains the active circuit is generated from entrainment maneuvers.

Purpose
To describe the electrophysiological characteristics of the circuits in patients with structural heart disease and previous left atrial ablation.

Methods
Consecutive patients with documented atypical flutter were included. A high density activation map was generated during the index arrhythmia and subsequently, entrainment maneuvers were performed to delineate the active circuit.

Results
Seventeen patients (82% males, average age 62+-7 years, 59% structural heart disease and 53% with a previous left atrial ablation) underwent 20 procedures. Twenty-one circuits were identified (20 in the left atrium and 1 in the right atrium). Of all LA circuits, 15 were macroreentrant (8 roof dependent, 4 perimitral and 3 related to a gap after AF ablation. Four out of 5 microreentrant circuits were related to the left atrial appendage and 1 was identified in the septum. Overall, procedural duration and fluoroscopy time was 176 ± 55 minutes and 27 ± 13 minutes, respectively. Roof-dependent ARTs and gap-related ARTs after AF ablation exhibited a significantly longer TCL (359 ± 99 ms and 331 ± 47 ms, respectively, p &lt; 0,05) than perimitral, microreentrant and RA circuits (279 ± 50 ms; 277 ± 36 ms; and 260 ms, respectively). Extensive areas of low voltage (&lt;0.3 mV) were identified in all patients with LA circuits.

Conclusions
The cycle length of complex atrial reentrant tachycardias is apparently related to the location and characteristics of the circuits. This feature can be of help at the time of approaching the mapping and ablation of this tachycardias.
P955Non-invasive mapping: what is the minimal number of electrodes needed to obtain a good spatial resolution of the activation map?
Authors: Parreira A L , Carmo P , Adragao P , Nunes S , Pinho J , Budanova M , Zubarev S , Goncalves P , Ferreira A , Cavaco D , Marques H 
Published: June 2020

Abstract

Introduction and aims
The 12-lead ECG is highly inaccurate for localization of the site of origin of supraventricular and ventricular arrhythmias. Non-invasive mapping systems (ECGI) based on a high number of electrodes recording the electrical activity on the surface of the torso have already proven good accuracy for mapping different arrhythmic substrates. The aim of this study was to assess what is the minimal number of leads needed to obtain a precise mapping with the ECGI.

Methods
This study enrolled 14 patients (9 male, median age 50 (44-58) years) referred to our center for catheter ablation of premature ventricular contractions (PVC). Patients underwent pre-procedural ECGI using the epicardial and endocardial mapping system . This system uses the DICOM images from contrast computed tomography of the heart and up to 28 adhesive electrodes with 8 leads each, adding up to 224 body-surface leads. All patients underwent invasive electroanatomical mapping and ablation with the magnetic navigation system. We analysed the number of recording leads used to construct the non-invasive activation map of the PVCs and the accuracy and the spatial resolution of the map when comparing to the invasive map. We then reprocessed the exam, using progressively less leads until we only left the leads placed in the standard 12 lead ECG positions and evaluated the concordance with the invasive map as well as the spatial resolution. We considered an earliest activation site (EAS) area of 1 cm2 a good spatial resolution and using a ROC curve we calculated the minimal number of leads necessary to obtain a good spatial resolution.

Results
The median number of electrodes used for the initial map was 170 (138-177). Concordance between non-invasive and invasive site of origin occurred in 11 out of 14 patients. The results are presented in the Table. The minimal number of electrodes to have a good spatial resolution was 100. The area of EAS was significantly lower when using more than 100 leads, respectively 0.65 (0.5-1) cm2 versus 3 (1.6-5) cm2, p &lt; 0.001.

Conclusions
The minimal number of leads to achieve a good spatial resolution was high. Reducing the number of leads resulted in a significant decrease in spatial resolution and a lower concordance rate.
ECGI data Number of adhesive electrodes Median number of leads Amycard/Carto concordance Median area of EAS in the ECGI (cm2) Maximal nº electrodes 170 (138-177) 11/14 0.64 (0.5-0.9) 12 electrodes 76 (61-80) 11/14 1.6 (1.4-2.6) 6 electrodes (2 Ant, 2 Lat ,2 Post) 38 (32-44) 9/14 4.3 (3.2-5.4) 12 leads 12 0/14 - Ant anterior; Lat: lateral; Post: posterior; EAS: early activation site.
Abstract Figure. Area of EAS according to the N of leads
P457Incidence of LA fibrosis and substrate-based AF ablation success rates in HF patients
Authors: Kirstein B , Neudeck S , Kronborg M B , El-Armouche A , Gaspar T , Piorkowski J , Wechselberger S , Zedda A , Tomala J , Mayer J , Wagner M , Ulbrich S , Richter U , Huo Y , Piorkowski C 
Published: June 2020

Abstract

Funding Acknowledgements
The author(s) received no specific funding for this work.

Background
In heart failure (HF) patients, sinus rhythm maintenance after catheter ablation for atrial fibrillation (AF) is mandatory to achieve better long-term outcome. Presence of left atrial (LA) fibrosis significantly attenuates ablation success rates. Incidence of LA fibrosis and the effect of an individualized substrate-based ablation concept on rhythm outcome in HF patients with AF is unclear.

Methods
This study investigated 103 patients (64 years, 69% men) with persistent AF (79%) and left ventricular (LV) dysfunction (EF 33% IQR [25; 38]) undergoing first time AF ablation. Identification of LA fibrosis and selection of ablation strategy were based on sinus rhythm voltage mapping. All patients received pulmonary vein isolation (PVI). LA fibrosis ablation was individualized by (i) homogenization of small areas, (ii) linear lesions connecting fibrosis and anatomical obstacles and (iii) linear lesions isolating large fibrotic areas. Rhythm outcome was measured by continuous device monitoring (AF detection ≥ 6 min) or Holter-ECG. A total post-procedural AF burden &lt; 0.1% was defined as successful rhythm control.

Results
LA fibrosis in the overall cohort, in paroxysmal and persistent AF patients was detected in 39/103 (38%), 6/22 (27%) and 33/81 (41%), respectively. After 11 ± 5 months and 1.2 procedures/patient, freedom from AF recurrence was similar between patients with and without LA fibrosis (33/39 (84%) vs. 54/64 (84%); p = 0.485). With continuous monitoring, 73/87 (84%) patients recorded a total AF burden &lt; 0.1%. There was no significant difference in AF burden outcome between patients with and without LA fibrosis (3.1% SD ±17.4 vs. 2.2% SD ±8.1; p = 0.4). No correlation between presence or extent of LA fibrosis and AF burden was found; p = 0.299.

Conclusion
A substantial number of HF patients with AF have no evidence of LA fibrosis. Among HF patients with LA fibrosis, individualized substrate-based AF ablation beyond PVI was able to achieve similar ablation success.